

ҚАЗАҚСТАН РЕСПУБЛИКАСЫ БІЛІМ ЖӘНЕ ҒЫЛЫМ МИНИСТРЛІГІ
Л.Н. ГУМИЛЕВ АТЫНДАҒЫ ЕУАЗИЯ ҰЛТТЫҚ УНИВЕРСИТЕТІ



ЖАС ҒАЛЫМДАР КЕҢЕСІ



Студенттер мен жас ғалымдардың
«ҒЫЛЫМ ЖӘНЕ БІЛІМ - 2016» атты
XI Халықаралық ғылыми конференциясының
БАЯНДАМАЛАР ЖИНАҒЫ

СБОРНИК МАТЕРИАЛОВ
XI Международной научной конференции
студентов и молодых ученых
«НАУКА И ОБРАЗОВАНИЕ - 2016»

PROCEEDINGS
of the XI International Scientific Conference
for students and young scholars
«SCIENCE AND EDUCATION - 2016»

2016 жыл 14 сәуір
Астана

**ҚАЗАҚСТАН РЕСПУБЛИКАСЫ БІЛІМ ЖӘНЕ ҒЫЛЫМ МИНИСТРЛІГІ
Л.Н. ГУМИЛЕВ АТЫНДАҒЫ ЕУРАЗИЯ ҰЛТТЫҚ УНИВЕРСИТЕТІ**

**Студенттер мен жас ғалымдардың
«Ғылым және білім - 2016»
атты XI Халықаралық ғылыми конференциясының
БАЯНДАМАЛАР ЖИНАҒЫ**

**СБОРНИК МАТЕРИАЛОВ
XI Международной научной конференции
студентов и молодых ученых
«Наука и образование - 2016»**

**PROCEEDINGS
of the XI International Scientific Conference
for students and young scholars
«Science and education - 2016»**

2016 жыл 14 сәуір

Астана

ӘӨЖ 001:37(063)

КБЖ 72:74

Ғ 96

Ғ96 «Ғылым және білім – 2016» атты студенттер мен жас ғалымдардың XI Халық. ғыл. конф. = XI Межд. науч. конф. студентов и молодых ученых «Наука и образование - 2016» = The XI International Scientific Conference for students and young scholars «Science and education - 2016» . – Астана: <http://www.enu.kz/ru/nauka/nauka-i-obrazovanie/>, 2016. – б. (қазақша, орысша, ағылшынша).

ISBN 978-9965-31-764-4

Жинаққа студенттердің, магистранттардың, докторанттардың және жас ғалымдардың жаратылыстану-техникалық және гуманитарлық ғылымдардың өзекті мәселелері бойынша баяндамалары енгізілген.

The proceedings are the papers of students, undergraduates, doctoral students and young researchers on topical issues of natural and technical sciences and humanities.

В сборник вошли доклады студентов, магистрантов, докторантов и молодых ученых по актуальным вопросам естественно-технических и гуманитарных наук.

ӘӨЖ 001:37(063)

КБЖ 72:74

ISBN 978-9965-31-764-4

©Л.Н. Гумилев атындағы Еуразия
ұлттық университеті, 2016

грибным фитопатогенам исследуемые штаммы микромицетов проявляли низкую активность относительно бактериальных, зоны подавления которых составляли 10,0-16,0 мм (табл. 2).

Нами было установлено, что 9 штаммов подавляли рост *Fusarium culmorum* (зоны от 14,0 до 60,0 мм) и *Cladosporium gerbarum* (зоны от 11,0 до 30,0 мм); 7 штаммов с разной степенью активности задерживали рост таких фитопатогенов как *Aspergillus niger* (зоны от 18,0 до 60,0 мм) и *Agrobacterium tumefaciens* (зоны от 11,0 до 22,0 мм). Некоторые штаммы обладали способностью задерживать рост *Fusarium oxysporum*, *Xanthomonas campestris*, *Fusarium moliniforme* и *Clavibacter michiganensis* (зоны от 11,0 до 52,0 мм). Для *Pseudomonas syringae* pv *lachymans* и *Alternaria alternata* удалось обнаружить только один штамм, который показал четкую зону задержки роста этих тест-культур диаметром 30,0 мм и 36,0 мм.

Таким образом, проведенные исследования по изучению антагонистического влияния почвенных микромицетов показали, что у 4-х штаммов антифунгальный спектр составляет в отношении 4-6 тест-культур, у 3-х штаммов антибактерицидное действие проявилось к 3 тест-культурам. Были также обнаружены штаммы, которые почти полностью подавляли рост *Aspergillus niger* и *Fusarium culmorum*, а также культуры, которые активно задерживали рост фитопатогенов.

Полученные результаты позволяют рассматривать выделенные из чернозема обыкновенного микромицеты как перспективные штаммы-антагонисты для получения биопрепаратов против грибов и бактерий – возбудителей болезней сельскохозяйственных растений.

Список использованных источников

1. Калантай Н.О. Економіко-екологічні інтенсифікації землеробства у світі // Міжнар. науково-практ. конф. «Актуальні проблеми сучасного землеробства» (м. Луганськ, 14-16 травня 2003 р.): доп. і виступи. – Луганськ: Вид-во ЛНАУ, 2003, с. 197-201.
2. Струнин Б.П., Струнина Т.Б., Кузьмина Л.Ю., Гуревич П.А. Фунгицидные свойства 3,3-диметил-1-(1,2,4-триазалил-1)-1-(4-хлорфенокси)-бутанона-2 // Вестник Казанского университета, № 6, ч. II, 2006, с. 57-70.
3. Методы экспериментальной микологии / Под. ред. В.И. Билай. – К.: Наукова думка, 1982, 432 с.
4. Руководство к практическим занятиям по микробиологии : учеб. пособие [3-е изд., перераб. и доп.] / Под. ред. Н. С. Егорова. – М.: Изд-во МГУ, 1995, 224 с.
5. Егоров Н. С. Основы учения об антибиотиках. – М.: Изд-во МГУ, 2004, 512 с.

3.2 Экология

UDC 615.45

PRIORITIZATION OF PHARMACEUTICALS IN THE SURFACE WATER OF KAZAKHSTAN

Aubakirova Bakhyt

aubakirova_bn@enu.kz

PhD student, L.N.Gumilyov Eurasian National University, Astana

Supervisors – prof. Boxall A.B.A., dr. Beisenova R.R., prof. Khanturin M.R.

Recent years studies have showed that pharmaceuticals enter to the environment as contaminants [1-2]. Many studies have reported the occurrence and fate of different classes of pharmaceuticals in the environment. It was found that surface waters, sewage effluents and freshwater sediments have the different concentration of drugs [3-6]. However, there is still

insufficient data, as ecotoxicity assessment was carried out only for several hundreds of pharmaceuticals from thousands of them [7]. Initially drugs constructed to treat human body and their interaction with the natural environment and biological species are poorly studied. In most cases, they have common properties as dangerous pollutants, because they can enter to the membranes and be persistent and in some cases their impact to the environment can be worthier than agricultural pollutants [8-9].

Pharmaceuticals mostly excrete via urine and feces unmetabolized, then discharge to wastewater treatment facilities (WWTF) and enter to the surface water [10-11]. Due to the various composition of each drug and including the fact that not all WWTF are capable to remove compounds of pharmaceuticals, it is impossible to predict their side effect to the environment and biological species. Therefore, active pharmaceutical ingredients (APIs) can be classified as toxic pollutants to aquatic environment [12].

Currently, there is less than 1% of APIs ecotoxicity data is available in literature and ecotoxicological database and still insufficient information on risk assessment of pharmaceuticals. Ecotoxicological study of each 3000 API will require a lot of time and money [9-10]. Therefore, it is important to establish a ranking system of pharmaceutical in order to detect those compounds and to prevent danger that they can pose to the environment and living organisms [13]. It is important to implement ranking of pharmaceuticals in Kazakhstan. Currently, pharmaceutical market in Kazakhstan is growing, in 2012 551.38 mln packages of drugs were sold in the country [14]. There are over 14000 objects of pharmaceutical activities, that is the highest percentage of private pharmaceutical structures in CIS [15-16]. A number of researchers have reported various prioritization approaches of APIs [17-18]. However, a major of studies require annual pharmaceutical usage data. The following methods cannot be applied to Kazakhstan, because until recently no studies have been found on pharmaceuticals hazard to the environment.

The aim of this study was to explore the main pharmaceuticals can pose hazard to the aquatic environment of Kazakhstan. APIs with the highest quantity of products were assumed as used oftenly and enter to the surface water. The study highlighted the widely used drugs that could lead to the risk in Kazakhstan. Vitamins and vaccines were excluded as they do not have a big effect to the aquatic environment or species. The paper describes 238 APIs that are used in Kazakhstan. It included antibiotics, antidepressants, non-steroidal anti-inflammatories (NSAIDs), blood lipid-lowering agents, hormones, tuberculosis (TB) and antitumor drugs.

Initially, the study considered approximately 2640 pharmaceuticals. Then, the list of APIs was made by using the online directory pharmaceuticals in Kazakhstan [19]. The each of APIs also contain the information of the daily intake, therapeutic class, concentration and number of products and as a result 841 substances were picked for the study. The lack of annual usage and sales data for the pharmaceuticals in Kazakhstan did not allow to generate the top usage pharmaceuticals. Therefore, it was decided to rely on the number of products of each APIs. The number of products of all APIs were obtained from the same directory Vidal pharmaceuticals. All compounds with less than 3 products were eliminated from the list.

Predicted environmental exposure was estimated based on products number, daily dose and metabolism. The data for the following assessment was obtained from the peer-reviewed papers and available online datasets [20-21].

The calculation of predicted no-effect concentrations (PNEC) was based on experimental or estimated aquatic ecotoxicity data. The data included EC50 and LC50 for fish, daphnia and algae with acute and chronic toxicity. All these data were collected from several database [22] and peer-reviewed papers. Estimation of PNEC based on relations of concentration of the most sensitive ecotoxicological data to safety factor. The calculation of safety factor was performed based on Technical guidance document on risk assessment proposed by European Commission [23].

There were some substances with no experimental data of toxicity. In order to fill the gap of them, QSAR Toolbox was used with read across approach of the Organisation for Economic Co-operation and Development.

In order to estimate the hazard of compounds in fish, we used fish plasma model (FPM) which was proposed Hugget et al [24]. Overall, this model compares the steady state concentration in fish plasma (FssPC) with the therapeutic plasma concentration in human (HtPC) (ratio of HtPC/FssPC). The information of HtPC was obtained from online databases [20, 25] and peer reviewed papers. FssPC was calculated by multiplying aqueous phase and fish arterial blood partition coefficient (Pbw) to exposure amount.

Totally, the study characterised 238 APIs for the prioritization. All compounds were highlighted by disease classes, which have been registered in health care institutions of Kazakhstan [16]. Each substance was considered based on predicted environmental exposure (Exposure:PNEC).

Table 1 provides information on drugs that pose the risk to the environment and have danger to the fish. The highest number of pharmaceutical products were found in the class of infectious and parasitical diseases (60 products). Overall, it was detected that paracetamol and hydrochlorothiazide had the top-notch number of products. However, the highest exposure was estimated on amoxicillin, clarithromycin, azithromycin, sulfamethoxazole and ketoconazole. Respiratory and cardiovascular diseases had the highest number of registered sickness rate.

Table 1. Top 20 highly ranked compounds

Ranking based on exposure	Ranking based on FssPC
Amoxicillin	Lisinopril
Clarithromycin	Orlistat
Azithromycin	Estradiol valerate
Sulfamethoxazole	Cinnarizine
Ketoconazole	Drotaverine
Meropenem	Estradiol
Naproxen	Clotrimazole
Oxytetracycline	Telmisartan
Ranitidine	Disulfiram
Diclofenac	Clemastine
Clotrimazole	Clopidogrel
Capreomycin	Terbinafine
Drotaverine	Azithromycin
Disulfiram	Diclofenac
Terbinafine	Montelukast
Moxifloxacin	Sertraline
Levofloxacin	Dextromethorphan
Beclomethasone	Miconazole
Clioquinol	Beclomethasone
Mycophenolic acid	Albendazole

Note: Bold highlighted pharmaceuticals show their common appearance in top ranking of drugs on exposure and FssPC

Even including the fact that ranking approach was different from previous studies, the results had some common compounds with some earlier prioritization research. Amoxicillin, clarithromycin, diclofenac and azithromycin were put in the list of high risk in ecotoxicological risk-based prioritization research by Guo et al (Table 1) [2]. Moreover, amoxicillin was identified as chemical with high hazard to aquatic ecosystem in the United Kingdom, Italy and Iran [26-28].

There are several same substances in exposure based ranking and FPM based ranking (Table 1). The majority of them are designed to treat infectious diseases and this class of disease has the highest number of products in APIs in Kazakhstan. Furthermore, several substances from the list have been concurred with previous works. For example, orlistat, montelukast, telmisartan, estradiol, clemastine and miconazole were also detected as priority chemicals in Roos et al study [29]. The highest value in FPM was estimated in Lisinopril. Previous studies did not include this substance to

the highest priority. However, Kostich et al research on measurement of concentration of APIs in effluent samples in US concluded that Lisinopril had the highest concentration value in terms of potential risks to humans [30].

Based on results it can be concluded these compounds should be considered in future research. The approach of ranking can be applied in countries with limited data to detect APIs of priority. Future research should investigate the analytical methods for these compounds and to monitor concentration.

Literature

1. Besse, J.-P., Kausch-Barreto, C. & Garric, J., 2008. Exposure Assessment of Pharmaceuticals and Their Metabolites in the Aquatic Environment: Application to the French Situation and Preliminary Prioritization. *Human and Ecological Risk Assessment: An International Journal*, 14(4), pp. 665-695.
2. Guo, J., Sinclair, C., Selby, K. & Boxall, A., 2016. Toxicological and ecotoxicological risk-based prioritization of pharmaceuticals in the natural environment. *Environmental Toxicology*, 9999(9999), pp. 1-10.
3. Halling-Sorensen, B. et al., 1998. Occurrence, Fate, and Effects of Pharmaceutical Substances in the Environment- a Review. *Chemosphere*, 32(2), pp. 357-393.
4. Daughton, C. & Ternes, T., 1999. Pharmaceuticals and personal care products. *Environmental Health Perspectives*, 107(6), pp. 907-938.
5. Brausch, J. M. & Rand, G. M., 2011. A review of personal care products in the aquatic environment: Environmental concentrations and toxicity. *Chemosphere*, 82(11), p. 1518-1532.
6. Monteiro, S. & Boxall, B., 2010. Occurrence and fate of human pharmaceuticals in the environment. *Reviews of Environmental Contamination and Toxicology*, Volume 202, pp. 53-154.
7. Berninger, J., LaLone, C., Villeneuve, D. & Ankley, G., 2015. Prioritization of pharmaceuticals for potential environmental hazard through leveraging a large-scale mammalian pharmacological dataset. *Environmental Toxicology and Chemistry*, 9999(9999), pp. 1-14.
8. Cooper, E., Siewicki, T. & Phillips, K., 2008. Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment. *Science of The Total Environment*, 398(1-3), pp. 26-33.
9. Sanderson, H. et al., 2004. Ranking and prioritization of environmental risks. *Regulatory Toxicology and Pharmacology*, Volume 39, pp. 158-183.
10. Donnachie, R., Johnson, A. & Sumpter, J., 2015. A rational approach to selecting and ranking some pharmaceuticals of concern for the aquatic environment and their relative importance compared with other chemicals. *Environmental Toxicology and Chemistry*, 9999(9999), pp. 1-7.
11. Hirscha, R., Ternes, T., Haberera, K. & Kratzb, K.-L., 1999. Occurrence of antibiotics in the aquatic environment. *Science of The Total Environment*, 225(1-2), pp. 109-118.
12. Kinney, C. A., Furlong, E. T., Werner, S. L. & Cahill, J. D., 2006. Presence and distribution of wastewater-derived pharmaceuticals in soil irrigated with reclaimed water. *Environmental Chemistry*, 25(2), pp. 317-326.
13. Munoz, I. et al., 2008. Ranking potential impacts of priority and emerging pollutants in urban wastewater through life cycle impact assessment. *Chemosphere*, Volume 74, pp. 37-44.
14. Tashenov, A. & Cherednichenko, N., 2013. *Development Prospects for the Pharmaceutical Markt of the Single Economic Space*, Almaty: Eurasian Development Bank.
15. Madiyarova, E., 2011. Status and prospects of development of the pharmaceutical industry of the Republic of Kazakhstan. *Herald KAFU*, Volume 3.
16. Ministry of healthcare and social development of the RK, 2015. *Health of the Republic of Kazakhstan and the activities of the health organization in 2014*, Almaty: Ministry of healthcare and social development of the RK.
17. Capleton, A. et al., 2006. Prioritising veterinary medicines according to their potential indirect human exposure and toxicity profile. *Toxicology Letters*, 163(3), pp. 213-223.

18. Diamond, J. et al., 2011. Prioritizing contaminants of emerging concern for ecological screening assessments. *Environmental Toxicology and Chemistry*, 30(11), pp. 2385-2394.
19. Vidal-Kazakhstan LLP, 2015. Vidal. [Online] Available at: <http://www.vidal.kz/> [Accessed October 2015].
20. Drugbank, 2013. Drugbank. [Online] Available at: <http://www.drugbank.ca/> [Accessed 2016].
21. ChEMBL, 2016. ChEMBL. [Online] Available at: <https://www.ebi.ac.uk/chembl/db/> [Accessed February 2016].
22. Pubmed, 2015. Open Chemistry Database. [Online] Available at: <https://pubchem.ncbi.nlm.nih.gov/> [Accessed November 2015].
23. TGD, 2003. Technical Guidance Document on Risk Assessment. [Online] Available at: https://echa.europa.eu/documents/10162/16960216/tgdpart2_2ed_en.pdf [Accessed 8 February 2016].
24. Huggett, D., Cook, J., Ericson, J. & Williams, R., 2003. A Theoretical Model for Utilizing Mammalian. *Human and Ecological Risk Assessment: An International*, 9(7), pp. 1789-1799.
25. Medsafe, 2015. New Zealand Medicines and Medical Device Safety and Authority. [Online] Available at: <http://www.medsafe.govt.nz/> [Accessed November 2015].
26. Boxall, A. et al., 2003. Prioritisation of veterinary medicines in the UK environment. *Toxicology Letters*, Volume 142, pp. 207-218.
27. Alighardashi, A., Rashidi, A., Neshat, A. & Golsefatan, H., 2014. Environmental Risk Assessment of Selected Antibiotics in Iran. *Iranian Journal of Health, Safety & Environment*, 1(3), pp. 132-137.
28. Zuccato, E., Castiglioni, S. & Fanelli, R., 2005. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. *J Hazard Mater.*, 122(3), pp. 205-209.
29. Roos, V. et al., 2012. Prioritising pharmaceuticals for environmental risk assessment: Towards adequate. *Science of the Total Environment*, Volume 421-422, pp. 102-110.
30. Kostich, S., Batt, A. & Lazorchak, J., 2014. Risks to aquatic organisms posed by human pharmaceutical use. *Environmental Pollution*, Volume 184, pp. 354-359.

UDC 628.4.04 .

REDUCE OF THE ECOLOGICAL LOAD ON THE ENVIRONMENT BY THE WASTE TREATMENT

Kapsalyamov A.B.

19575859@mail.ru

Master student at KazUTB, Astana

The environment is a condition for the existence of living organisms together with human being. In order to improve the quality of life, human transforms the environment to fit his needs. This inadvertently changes the constancy of the composition of the internal environment. Thermodynamic principles and laws of conservation of energy, matter and information are closely related with each other. As an example, it is possible to consider the flow of energy and material information in the system, which should cover the entire system. Currently, there are quite a large number of calculations in a matter of improving environmental quality. For example the water flow in the biological specimen takes hours, the moisture in the atmosphere (hence in aerobiosphere) - 8 days, free continental surface water - from 16 days in rivers, and up to 17 years in lakes, groundwater is updated in 1400 years, and the ocean water in 2500 years. Similarly, the specified time of energy and metabolism transition exist in all natural systems.